# Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization

> **NCT00681603** · NA · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 13 (actual)

## Conditions studied

- Lipid Keratopathy
- Penetrating Keratoplasty
- Herpetic Keratopathy
- Rosacea

## Interventions

- **DRUG:** subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)

## Key facts

- **NCT ID:** NCT00681603
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2008-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00681603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00681603, "Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00681603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*